RT Journal Article
SR Electronic
T1 Random effects modelling vs logistic regression for the inclusion of cluster level covariates in propensity scores for medical device and surgical epidemiology
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.02.22269820
DO 10.1101/2022.02.02.22269820
A1 Du, Mike
A1 Prats-Uribe, Albert
A1 Khalid, Sara
A1 Prieto-Alhambra, Daniel
A1 Strauss, Victoria Y
A1 Khalid, Sara
YR 2022
UL http://medrxiv.org/content/early/2022/02/03/2022.02.02.22269820.abstract
AB Purpose Surgeon and hospital related features such as surgeries volume can be associated with treatment choices and treatment outcomes. Accounting for these covariates with propensity score (PS) analysis can be challenging due to clustered nature of the data. Previous studies have not focused solely on the PS estimation strategy when treatment effects are estimated using random effects model(REM). We studied PS estimation for clustered data using REM compared with logistic regression.Methods Six different PS estimation strategies were tested using simulations with variable cluster-level confounding intensity (odds ratio(OR)=1.01 to OR=2.5): i) logistic regression PS excluding cluster- level confounders; ii) logistic regression PS including cluster-level confounders; iii) same as ii) but including cross-level interactions; iv), v) and vi), similar to i), ii) and iii) respectively but using REM instead of logistic regression PS. Same analysis were tested in a randomised controlled trial emulation of partial vs total knee replacement surgery. Simulation metrics included bias and mean square error (MSE). For trial emulation, we compared observational vs trial-based treatment effect estimates.Results In most simulated scenarios, logistic regression including cluster-level confounders gave more accurate estimates with the lowest bias and MSE. E.g. with 50 clusters x 200 individuals and confounding intensity OR=1.5, the relative bias= 10% and MSE= 0.003 for (i), compared to 21% and, 0.010 for (iv). In the Trial emulation, all 6 PS strategies gave similar treatment effect estimates.Conclusions Logistic regression including patient and surgeon/hospital-level confounders appears to be the preferred strategy for PS estimation. Further investigation with more complex clustered structure is suggested.Competing interests Prof. Prieto-Alhambra’s research group has received grant support from Amgen, Chesi-Taylor, Novartis, and UCB Biopharma. His department has received advisory or consultancy fees from Amgen, Astellas, AstraZeneca, Johnson, and Johnson, and UCB Biopharma and fees for speaker services from Amgen and UCB Biopharma. Janssen, on behalf of IMI-funded EHDEN and EMIF consortiums, and Synapse Management Partners have supported training programs organised by DPA’s department and open for external participants organized by his department outside submitted work.Ethics Approval and Informed Consent This study was approved by the secretary of state, having considered the recommendation from the Confidentiality Advisory Group (CAG reference: 17/CAG/0174). Informed ethical approval was given on the use of pseudonymised patients data included in the study.Competing Interest StatementProf. Prieto-Alhambra's research group has received grant support from Amgen, Chesi-Taylor, Novartis, and UCB Biopharma. His department has received advisory or consultancy fees from Amgen, Astellas, AstraZeneca, Johnson, and Johnson, and UCB Biopharma and fees for speaker services from Amgen and UCB Biopharma. Janssen, on behalf of IMI-funded EHDEN and EMIF consortiums, and Synapse Management Partners have supported training programs organised by DPA's department and open for external participants organized by his department outside submitted work.Funding StatementProf. Prieto-Alhambra's research group has received grant support from Amgen, Chesi-Taylor, Novartis, and UCB Biopharma. His department has received advisory or consultancy fees from Amgen, Astellas, AstraZeneca, Johnson, and Johnson, and UCB Biopharma and fees for speaker services from Amgen and UCB Biopharma. Janssen, on behalf of IMI-funded EHDEN and EMIF consortiums, and Synapse Management Partners have supported training programs organised by DPA's department and open for external participants organized by his department outside submitted work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the secretary of state, having considered the recommendation from the Confidentiality Advisory Group (CAG reference: 17/CAG/0174). Informed ethical approval was given on the use of pseudonymised patients data included in the study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the correspondence author Prof Daniel Prieto-AlhambraPSpropensity score;ORodd ratio;REMrandom effects model;MSEmean square error;UKRunicompartmental knee replacement;TKRtotal knee replacement;NJRUK National Joint Registry